According to the recent research report titled ‘Global Tourette syndrome Treatment Market is segmented by Product (Antipsychotics and Non-Antipsychotics), Regional Forecasts 2021-2027’, available with MarketStudyReport, global Tourette syndrome treatment market is expected to record a CAGR of 10.41% over 2021-2027.
 

As per the report findings, global Tourette syndrome treatment market growth is primarily driven growing emphasis on the syndrome research and increasing cases of the disorder.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/4219652/
 

According to the CDC (Centers for Disease Control and Prevention), one out of every 360 (0.3%) children aged 6 to 17 in the United States has been diagnosed with TS, a total of around 138,000 children. Furthermore, it has been found that 37% of children diagnosed with TS had moderate or severe disorders or problems.
 

The CDC is also working with the Tourette Association of America to expand CBIT (Comprehensive Behavioral Intervention for Tics) access, offer education and outreach, enhance adoption, and lower stigma through the Tourette Association Youth Ambassador Program, while providing resources to help individuals and families living with Tourette, such as school resources. Such initiatives between authorities will positively influence industry development through 2027.
 

For the uninitiated, Tourette syndrome is a neurological condition characterized by physical and vocal tics. Tics are non-rhythmic, repetitive contractions of a single muscle group caused by a genetic defect that prevents the brain from producing histamine.
 

A breakdown in the balance of neurotransmitters in the brain, which transfer nerve signals from cell to cell, is the primary cause of the condition. The use of inappropriate words or making socially incorrect statements is linked to this syndrome.
 

Speaking of challenges in worldwide Tourette syndrome treatment industry, lack of awareness in developing economies is likely to act as major obstacle for healthcare providers and related companies in this domain.
 

Elaborating on geographical ambit, North America presently accounts for considerable industry share, owing to presence of key players in the region. On the other hand, Europe has emerged as a major market due to the high rate of Tourette syndrome in this geography.
 

Meanwhile, Asia Pacific market value is expected to increase significantly over 2021-2027, attributable to increasing number of patients and rising cognizance about the ailment.
 

Coming to competitive landscape, Zydus Pharmaceuticals (USA) Inc., Teva Pharmaceuticals Industries Ltd., Pfizer Inc., Catalyst Pharmaceuticals Inc., Mylan N.V., Reviva Pharmaceuticals Inc., Auspex Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, AstraZeneca plc, and Otsuka Holdings Co. Ltd. are the major companies operating in global Tourette syndrome treatment market sphere.